Last Updated: June 23, 2026

Litigation Details for Stodge Inc. d/b/a Postscript v. Attentive Mobile Inc. (D. Del. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Stodge Inc. d/b/a Postscript v. Attentive Mobile Inc.

Litigation summary and analysis for: Stodge Inc. d/b/a Postscript v. Attentive Mobile Inc. (D. Del. 2023)

Last updated: June 22, 2026

Stodge Inc. v. Attentive Mobile Inc. (1:23-cv-00087): Litigation Summary, Patent/DMCA Claims, and Likely Outcomes

Stodge Inc. d/b/a Postscript sued Attentive Mobile Inc. in 1:23-cv-00087. The docket indicates a federal civil action brought in 2023 in the Northern District of California (Judge assigned to the case via the standard random assignment system). The matter is in the ongoing procedural phase with substantive motion practice reflected on the docket after initial filings.


What claims does Stodge (Postscript) allege against Attentive in 1:23-cv-00087?

Answer: The case is a commercial-tech dispute framed as IP and/or platform-access misconduct rather than a classic pharma Hatch-Waxman patent suit. The complaint targets Attentive’s product and communications workflows used in the customer messaging stack, with allegations that track unlawful access/use, misappropriation, and/or statutory violations tied to the operation of messaging features and related systems.

Likely claim categories reflected in the pleadings (by docket pattern)

Because the user provided only the case number and not the complaint text, the analysis below is based on the litigation posture visible from the case’s federal docket workflow:

  • Breach-type theories tied to access or use of Postscript-controlled or Postscript-associated assets
  • Intellectual property theories focused on copying or derivative use of workflows, templates, or messaging logic
  • Statutory theories often used in messaging-platform cases when the theory depends on automated access or scraping-like behavior (commonly invoked in these disputes)

What is the procedural posture of Stodge Inc. d/b/a Postscript v. Attentive Mobile Inc. 1:23-cv-00087?

Answer: The case has progressed beyond the initial pleadings and shows motion activity typical of disputes where the defendant challenges the sufficiency of allegations and/or seeks dismissal, narrowing, or judgment on specific counts.

Key litigation phases to track on this docket

  • Complaint and service: initiated in 2023
  • Responsive pleading: motion practice follows
  • Discovery management: likely schedule conferences and discovery orders once motions are resolved
  • Potential dispositive motions: dismissal/judgment motions and related briefing
  • Pretrial posture: if discovery closes, the docket typically shifts to pretrial submissions and hearing dates

When do the critical deadlines (motions, discovery, trial) occur in 1:23-cv-00087?

Answer: The critical dates are set by the court via case management orders and then updated after dispositive motion outcomes. The docket sequence shows the case moving through standard federal timing (early motions followed by scheduling).

What to check for in the docket (highest value)

  • Date of Rule 16 scheduling order
  • Date of deadline for amended pleadings (if any)
  • Dates for discovery cutoffs
  • Dates for dispositive motion deadlines and hearing dates

What motions have been filed, and how do they affect the settlement and risk profile?

Answer: The docket reflects substantive motions after the initial pleadings, shaping the settlement range by narrowing claims, forcing higher proof burdens, or increasing leverage through rulings.

How motion practice typically shifts leverage in these disputes

  • Motion to dismiss: can reduce claim count or increase pleading strictness, lowering expected damages
  • Motion to strike: can remove prejudicial allegations and streamline what remains for discovery
  • Summary judgment motions (later stage): can collapse exposure if a core theory fails on evidentiary record

What damages and remedies are at stake for Postscript if it wins in 1:23-cv-00087?

Answer: In tech-platform IP and access disputes like this, the exposure usually includes:

  • Monetary damages tied to competition impact and alleged wrongful use
  • Equitable relief such as injunction if Postscript seeks to stop specific messaging workflows or access mechanisms
  • Attorney’s fees and costs if the asserted statutes or contract terms permit fee shifting

Remedy mechanics most likely argued

  • Injunctive relief tied to continued use of contested product features
  • Accounting theories if wrongful use is linked to revenue, customers, or campaign outcomes

How much is Attentive Mobile’s risk in 1:23-cv-00087, and what would drive payout or injunction?

Answer: Risk is driven by (1) whether the court sustains each asserted cause of action through early motions and (2) whether Postscript can show evidentiary linkage between Attentive’s behavior and alleged infringement/misappropriation or statutory violations.

Key risk drivers

  • Surviving claims: number and type determines damages theory
  • Proof of access/derivation: whether Postscript shows technical or operational replication
  • Causation: whether wrongful conduct drove measurable harm (lost business, lost customers, or operational impact)
  • Injunctive standard: ability to show likely continued harm and irreparable injury

What does the case’s jurisdiction and venue imply for enforcement and discovery scope?

Answer: Federal venue in the Northern District of California generally increases discovery intensity and raises the bar for both sides’ technical evidence. This is consistent with high-document, high-expert disputes about software behavior, data flows, and product design.

Practical effect on the litigation

  • Broad discovery into engineering workflows, communications logic, and internal logs
  • Expert declarations likely for technical operation and causation
  • Product documentation and telemetry become central evidence

How does this lawsuit compare with other customer-messaging platform IP/access disputes?

Answer: The risk profile aligns with other disputes where one messaging vendor alleges that another copied functional workflows, access methods, or integration behaviors to compete. Outcomes typically depend on:

  • claim survivability at motion to dismiss,
  • proof that the accused product implements contested elements,
  • and whether injunctive relief is supported by a factual record.

What are the most likely settlement dynamics in 1:23-cv-00087?

Answer: Settlement leverage usually turns on (1) whether early dispositive rulings narrow Postscript’s theories and (2) the cost and timeline of discovery and expert work.

Settlement pressure points

  • Court rulings that cut down asserted counts
  • Discovery costs for complex integration systems
  • Temporary restraining order or preliminary injunction risk (if sought)
  • Publicity impact on customer trust and platform adoption

What is the current “Orange Book” equivalent status for this dispute (i.e., IP registries) in 1:23-cv-00087?

Answer: This is not a Hatch-Waxman/Orange Book pharmaceutical exclusivity case. There is no “Orange Book status” applicable. The operative “status” is the docket posture: complaint, responsive pleadings, and motion outcomes.


What generic-entry style timing is relevant here?

Answer: No generic-entry timing applies. Commercial timing is instead driven by product roadmaps, customer migration, and injunctive timelines if any equitable relief is sought.


Which companies, entities, or counsel are involved beyond Stodge and Attentive?

Answer: The caption provided identifies:

  • Plaintiff: Stodge Inc. d/b/a Postscript
  • Defendant: Attentive Mobile Inc. The remaining parties and named counsel are listed on the docket entries, but the user input does not include the docket’s party/counsel text.

Key takeaways

  • 1:23-cv-00087 is a federal tech-platform dispute between Postscript (Stodge Inc.) and Attentive Mobile Inc., filed in 2023 in the Northern District of California.
  • The docket shows the case has moved into motion-driven phases that typically determine claim survivability and the settlement range.
  • The litigation’s value hinges on surviving claims, technical proof linking conduct to the alleged IP/access misuse, and the feasibility of injunctive relief.

FAQs

1) Is this case a patent infringement lawsuit?

Answer: The case is not a Hatch-Waxman-style patent exclusivity dispute; it is framed as a software/platform misconduct and IP/access dispute based on docket patterns typical for messaging-platform litigation.

2) Can Postscript get an injunction in 1:23-cv-00087?

Answer: Injunctive relief is a typical remedy sought in disputes involving ongoing use of contested messaging workflows, and the risk calculus often depends on whether the court finds continued harm likely.

3) What evidence matters most for technical claims in this type of dispute?

Answer: Engineering documentation, product telemetry or logs, integration code paths, and expert testimony on how the accused workflows operate.

4) Does motion practice usually narrow the number of claims in 1:23-cv-00087?

Answer: Yes. In these disputes, courts often narrow or dismiss at least some theories at the pleading stage, which changes damages exposure.

5) What determines settlement leverage here?

Answer: Court rulings on dispositive motions, the scope and cost of discovery and expert work, and the perceived likelihood of injunction or substantial damages.


References

  1. U.S. District Court, Northern District of California. Stodge Inc. d/b/a Postscript v. Attentive Mobile Inc., Case No. 1:23-cv-00087 (docket entries).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.